

## MEDICINES VALUE GROUP

### WORK PLANNED: NEW and IN PROGRESS (by SPECIALTY)

Updated 16<sup>th</sup> June 2021

- This list of new and 'in progress' formulary work updated every 2 months.
- Items in bold have potential for ICS alignment or are being worked on across the ICS.
- If there any queries please email [bucks.medicinesresourcecentre@nhs.net](mailto:bucks.medicinesresourcecentre@nhs.net)

| New medicine applications / guidelines: discussion and preliminary decisions   |  |
|--|--|
| <b>ANAESTHETICS / ICU</b><br><b>New</b> <ul style="list-style-type: none"> <li>• Sugammadex wider criteria for use</li> </ul>  |  |
| <b>CARDIOLOGY</b><br><b>Outstanding</b><br><b>Apr 21.11</b> <ul style="list-style-type: none"> <li>• <b>Dapagliflozin for heart failure guideline</b></li> <li>• <b>Updated Chronic Heart failure guideline.</b></li> <li>• <b>SGLT2 inhibitor initiation checklist</b></li> </ul>   |  |
| <b>CARDIOLOGY/ LIPIDOLOGY</b><br><b>New</b> <ul style="list-style-type: none"> <li>• <b>Bempedoic acid with ezetimibe for treating primary hypercholesterolaemia or mixed dyslipidaemia NICE TA 694</b></li> <li>• Updated Lipid modification guideline</li> <li>• PCSK9 inhibitors – revised formulary restrictions</li> </ul>  |  |
| <b>DERMATOLOGY</b><br><b>New</b> <ul style="list-style-type: none"> <li>• <b>5 Fluorouracil for Bowen's disease</b></li> </ul> <b>Outstanding</b> <ul style="list-style-type: none"> <li>• <b>July 19.30</b> Updated Acne guideline</li> <li>• <b>Tildrakizumab for Plaque Psoriasis NICE TA575</b><br/>Blueteq form</li> <li>• <b>Certolizumab for plaque psoriasis NICE TA 574</b><br/>Blueteq form</li> </ul> |  |

|  |              |
|--|--------------|
| <p><b>ENDOCRINOLOGY</b><br/>New</p> <ul style="list-style-type: none"> <li>• Basal insulins review</li> <li>• Oral semaglutide for Type 2 Diabetes.</li> <li>• Updated position of GLP1 agonists and SGLT2 inhibitors for Type 2 Diabetes following updated CV evidence and EASD / ESC guidance.</li> <li>• Update Blood glucose lowering Type 2 Diabetes guideline and initiation checklists</li> <li>• Update Type 2 Diabetes Blood glucose meters guideline including revised position of CSII / CGM / FGMS</li> <li>• Updated Somatropin in adults shared care protocol</li> </ul> <p>Outstanding</p> <ul style="list-style-type: none"> <li>• Sep 20.15a Updated High Strength insulins guideline</li> <li>• <b>Sept 19.20 – Formulary review of specific CGM devices in type 1 diabetes: TVPC 64 and 89</b></li> <li>• May 19b.19 Freestyle Libre Blueteq form</li> <li>• April 21.12 Liraglutide for managing overweight and obesity, NICE TA 664 Prescribing arrangements</li> </ul> | <p>Maire</p> |
| <p><b>ENT</b><br/>Outstanding<br/>Mar 19.19 Intranasal steroids traffic light review</p>   |              |
| <p><b>GASTROENTEROLOGY</b><br/>New</p> <ul style="list-style-type: none"> <li>• Vedolizumab subcutaneous</li> <li>• Infliximab biosimilar</li> <li>• Infliximab subcutaneous</li> <li>• Rifaximin for HE – updated criteria for use</li> </ul> <p>Outstanding</p> <ul style="list-style-type: none"> <li>• July 20.14b Updated Biologics in UC algorithm</li> <li>• July 20.14a Ustekinumab for UC NICE TA blueteq form</li> <li>• Feb 18.11 Tacrolimus traffic light classification review</li> </ul>   |              |
| <p><b>GENDER DYSPHORIA</b><br/>Outstanding<br/>Apr 21.25 Tavistock SC Guideline for treatment of Gender Dysphoria in people assigned male at birth transitioning to a female gender identity</p>   |              |
| <p><b>GYNAECOLOGY / MENOPAUSE</b><br/>Outstanding</p> <ul style="list-style-type: none"> <li>• Sept 19.26 HRT / Menopause guideline including micronized progesterone / testosterone gels and updated NICE NG23</li> </ul>   |              |

|  |  |  |
|--|--|--|
|  | <p><b>HAEMATOLOGY</b><br/><b>New</b></p> <ul style="list-style-type: none"> <li>• Andexanet alfa for reversing anticoagulation from apixaban or rivaroxaban, NICE TA 697</li> <li>• <b>Cyanocobalamin (BSH guidance</b></li> <li>• <b>Updated Dalteparin traffic light classification and guideline</b></li> <li>• Updated DOACs for VTE formulary restrictions and guideline</li> <li>• Updated VTE Thromboprophylaxis guideline (taking into account the above revised formulary changes)</li> </ul> <p><b>Outstanding</b></p> <ul style="list-style-type: none"> <li>• July 20.22 Updated DOAC restrictions to support warfarin to DOAC switching during COVID-19 guideline</li> <li>• <b>Apr 21.26</b> Updated DOAC for AF hospital formulary restrictions</li> </ul>  |  |
|  | <p><b>MICROBIOLOGY</b><br/><b>Outstanding</b><br/>Jul 19.13 Ceftriaxone infusor audit results</p>  |  |
|  | <p><b>NEUROLOGY</b><br/><b>New</b></p> <ul style="list-style-type: none"> <li>• Ofatumumab for relapsing multiple sclerosis, NICE TA 699, May 2021</li> <li>• : Natalizumab (subcutaneous) for the treatment of adults with highly active relapsing-remitting multiple sclerosis (TA127) and : NHSE SSC2256</li> <li>• <b>Glycopyrronium for drooling in Parkinson's disease: proposed traffic light reclassification</b></li> <li>• <b>Rotigotine patches for Parkinson's disease – proposed traffic light reclassification</b></li> <li>• <b>Apomorphine 5mg/ml injection Dacepton®</b></li> <li>• <b>Perampanel and zonisamide for epilepsy: traffic light classification review and guidelines decision</b></li> <li>• <b>Natalizumab s/c injection</b></li> </ul> <p><b>Outstanding</b></p> <ul style="list-style-type: none"> <li>• Jan 20.3b Updated restless leg syndrome guideline including place of MR preparations</li> <li>• Dec 19.10 Xeomin (botulinum neurotoxin type A) for chronic sialorrhoea - NICE TA 605 - update Botulinum toxin guideline</li> <li>• Dec 19.10 Xeomin (botulinum neurotoxin type A) for chronic sialorrhoea - NICE TA 605 Blueteq form</li> <li>• <b>Apr 21.21 CGRP mAbs for migraine guideline</b></li> </ul> |  |
|  | <p><b>ONCOLOGY</b><br/><b>New</b><br/>Gelclair sachets for specific patient groups receiving chemotherapy</p> <p><b>Outstanding</b><br/><b>Dec 16.2 Goserelin for breast cancer</b></p>  |  |

|  |  |  |           |   |           |   |           |   |  |
|--|--|--|-----------|---|-----------|---|-----------|---|--|
| <p><b>OPHTHALMOLOGY</b><br/><b>New</b></p> <ul style="list-style-type: none"> <li>• Ketotifen preservative free eye drops</li> <li>• TVPC97 – Immunotherapy for allergic rhino conjunctivitis – <b>New January 2020</b></li> <li>• <b>Botox for Squint</b></li> <li>• Serum eye drops for severe ocular surface disease<br/>NHSE Clinical Commissioning Policy<br/><a href="https://www.england.nhs.uk/publication/serum-eye-drops-for-the-treatment-of-severe-ocular-surface-disease-all-ages/">https://www.england.nhs.uk/publication/serum-eye-drops-for-the-treatment-of-severe-ocular-surface-disease-all-ages/</a></li> </ul> <p><b>Outstanding</b></p> <table border="1" data-bbox="225 577 727 1066"> <tr> <td>Dec 19.15</td> <td>Bevacizumab intravitreal injection for rare, sight threatening eye conditions.</td> </tr> <tr> <td>Sep 19.13</td> <td>Updated Dexamethasone and ranibizumab 1st line BRVO Blueteq forms</td> </tr> <tr> <td>Sep 19.10</td> <td>Fluocinolone for non-infectious uveitis NICE TA 590</td> </tr> <tr> <td>Sep 19.11</td> <td>Updated Intravitreals algorithm and Uveitis guideline</td> </tr> </table> <p><b>Apr 21.13a and b</b></p> <ul style="list-style-type: none"> <li>• <b>Brolucizumab for wet age-related macular degeneration, NICE TA 672 Blueteq form</b></li> <li>• <b>Brolucizumab for wet AMD audit</b></li> <li>• <b>Updated Intravitreals algorithm</b></li> </ul> | Dec 19.15  | Bevacizumab intravitreal injection for rare, sight threatening eye conditions. | Sep 19.13 | Updated Dexamethasone and ranibizumab 1st line BRVO Blueteq forms | Sep 19.10 | Fluocinolone for non-infectious uveitis NICE TA 590 | Sep 19.11 | Updated Intravitreals algorithm and Uveitis guideline |  |
| Dec 19.15  | Bevacizumab intravitreal injection for rare, sight threatening eye conditions. |  |           |   |           |   |           |   |  |
| Sep 19.13  | Updated Dexamethasone and ranibizumab 1st line BRVO Blueteq forms              |  |           |   |           |   |           |   |  |
| Sep 19.10  | Fluocinolone for non-infectious uveitis NICE TA 590                            |  |           |   |           |   |           |   |  |
| Sep 19.11  | Updated Intravitreals algorithm and Uveitis guideline                          |  |           |   |           |   |           |   |  |
| <p><b>ONE RECORDER BUCKS (ORB)</b><br/><b>Outstanding</b><br/>Jan 20.12 Buprenorphine Espranor</p>   |  |  |           |   |           |   |           |   |  |
| <p><b>OXFORD HEALTH</b><br/><b>New</b></p> <ul style="list-style-type: none"> <li>• <b>Updated GAD formulary and guideline</b></li> <li>• Updated Dementia pathway to reflect updated NICE NG 217 recommendation 1.3 reflected in updated NICE NG97, June 2018</li> <li>• NICE CG185: Updated Bipolar depression guideline in response to NICE CG185 updated Feb 20 (updated CG)</li> <li>• <b>Melatonin in adults</b></li> <li>• <b>Depression in &lt;18 years guideline</b></li> </ul> <p><b>Outstanding</b></p> <ul style="list-style-type: none"> <li>• <b>Apr 21.8b Updated ADHD in Adults Shared Care Protocol</b></li> <li>• <b>April 21.6 Melatonin for ADHD patients transitioning from Paeds to Adult.</b></li> </ul>  |  |  |           |   |           |   |           |   |  |

|  |   |  |
|--|---|--|
|  | <p><b>PAEDIATRICS</b><br/><b>New</b></p> <ul style="list-style-type: none"> <li>• <b>Omeprazole liquid</b></li> <li>• Dexmedetomidine for MRI in Paeds</li> <li>• <b>Somatropin brandS update</b></li> </ul> <p><b>Outstanding</b></p> <ul style="list-style-type: none"> <li>• <b>CGM for Paeds Blueteq form</b></li> <li>• <b>Sept 20.23.24</b> Guideline for the Use of Nutrient Enriched Post Discharge Formula (NEPDF) for Premature and or Low Birth Weight Infants</li> </ul>  |  |
|  | <p><b>PAIN</b><br/><b>New</b></p> <ul style="list-style-type: none"> <li>• Lidocaine plaster for neuropathic pain</li> <li>• Gabapentin cream for neuropathic pain</li> <li>• Amitriptyline cream for neuropathic pain</li> <li>• Updated neuropathic pain guideline to incorporate LP, GC, AC.</li> <li>• Updated Acute pain guideline</li> <li>• guideline</li> </ul>   |  |
|  | <p><b>PALLIATIVE CARE</b><br/><b>Outstanding</b></p> <p>Dec 19.5c Updated neuropathic pain in palliative care guideline</p>   |  |
|  | <p><b>RADIOLOGY</b><br/><b>New</b></p> <p>Omeron and Optiray 350 . Alison Reid, Lead for CT.</p>  |  |
|  | <p><b>RENAL</b><br/><b>Outstanding</b></p> <p><b>Hyperkalaemia guideline in response to:</b></p> <ul style="list-style-type: none"> <li>• <b>July 20.21 Patiromer for treating hyperkalaemia – NICE TA 623, Feb 2020</b></li> <li>• <b>Dec 19.18 Sodium zirconium cyclosilicate for hyperkalaemia in accordance with NICE TA 599, Sept 19</b></li> </ul>  |  |
|  | <p><b>RESPIRATORY</b><br/><b>New</b></p> <ul style="list-style-type: none"> <li>• New inhalers for COPD</li> <li>• Environmentally friendly inhalers</li> <li>• Updated COPD guideline to align with NICE</li> <li>• New inhalers for Asthma</li> <li>• Updated Asthma guideline</li> <li>➤ Mologic new products (AHSN).To predict / identify acute exacerbations of COPD for patients at home</li> <li>➤ GP-based blood test to differentiate between eosinophilic and neutrophilic causes of COPD exacerbations</li> </ul> <p><b>Outstanding</b></p> <ul style="list-style-type: none"> <li>• <b>Mar 19.27 Mycophenolate traffic light classification review and updated guideline</b></li> <li>• <b>Dec 15.9 Azithromycin for non-CF bronchiectasis</b></li> </ul> |  |

|   |  |  |
|---|--|--|
|   | <p><b>RHEUMATOLOGY</b><br/><b>New</b></p> <ul style="list-style-type: none"> <li>Anakinra for treating Still's disease, NICE TA 685, Mar 21I</li> <li>Updated Vit D guideline pp. during COVID</li> </ul> <p><b>Outstanding</b></p> <ul style="list-style-type: none"> <li><b>Sep 19.41 updated Gout guideline (re. Febuxostat and new appendix)</b></li> <li>Jan 19.6 updated Biologics in Psoriatic Arthritis algorithm</li> <li><b>Feb 18.8 Golimumab for AS NICE TA 497 blueteq form</b></li> <li><b>Dec 17.18 Sarilumab for rheumatoid arthritis NICE TA 485 Blueteq form</b></li> <li><b>Apr 21.15 Filgotinib for moderate to severe RA NICE TA 676 Blueteq form</b></li> <li><b>Apr 21.16 Upadacitinib for severe rheumatoid arthritis, NICE TA 665 Blueteq form</b></li> <li><b>Apr 21.17 Updated Biologics in rheumatoid arthritis algorithm</b></li> </ul> |  |
|   | <p><b>RHEUMATOLOGY and OPHTHALMOLOGY</b></p> <ul style="list-style-type: none"> <li>Hydroxychloroquine retinal screening updated RCOph guidance</li> <li>Updated Hydroxychloroquine shared care protocol</li> </ul>  |  |
|   | <p><b>SPINAL</b><br/><b>Outstanding</b><br/>Dec 19.5c Update Spinal Chronic pain guideline</p>   |  |
|   | <p><b>STROKE</b><br/><b>New</b></p> <ul style="list-style-type: none"> <li>Updated Lipid modification guideline reflecting specific requirements for stroke patients</li> <li>Nicardipine IV for acute hypertension</li> <li>Updated acute Stroke guideline</li> </ul>   |  |
|   | <p><b>UROLOGY</b><br/><b>Outstanding</b></p> <ul style="list-style-type: none"> <li>Jan 20.15 Bladder pain syndrome</li> <li>April 21.32 Update Bucks Erectile Dysfunction treatment algorithm to reflect the TVPC policy 34 v. 2.1 Jan 2021</li> </ul>  |  |
| <p><b>MVG Governance / Bucks Formulary Policy</b></p> |  |  |

|  |  |  |
|--|--|--|
|  | <p><b>New</b></p> <p>Updated Medicines Policy Annexe 19 Outpatient Recommendation and Prescribing Policy during COVID</p> <p><b>Outstanding</b></p> <p><b>Sep 19.49</b> Annual DOI form template Feedback</p> <p><b>Mar 19.21</b> Comparison of draft MVG ToR and previous FMG ToR for confirmation and approval</p> <p>Medicines Policy Annexe 3 Bucks formulary policy proposed amendments:</p> <p><b>Mar 19.16b</b> Criteria for presence of a consultant for a NICE TA new medicine (approved Dec 17)</p> <p><b>Sep 19.15</b> – Role of rebates in formulary decision making</p> |  |
| <b>Regional Medicines Optimization Committees (RMOC) and Thames Valley Priorities Committee (TVPC)</b> |  |  |
|  | <p><b>Outstanding</b></p> <p><b>Jan 20.24a</b> RMOC Free of Charge (FOC) Medicines Schemes: Updated Advice for adoption as local policy</p> <p><b>May 18.19, Jan 20.21, April 21 AOB</b></p> <p>Shared care guidance of NHSE and RMOC comparison with and updated of Bucks responsibilities for amber protocol drugs</p>   |  |